CLC bio develops widely cited desktop, enterprise and cloud software for analysis of biological data. While offering some open source algorithms with their tools, CLC bio have their own implementations of several popular applications, which have been accelerated using SIMD technology. In 2010, CLC bio was the first commercial platform for bioinformatics analysis that utilized a graphical user interface for building, managing, and deploying analysis workflows. Among other features, the software supports read mapping of Sanger and high-throughput sequencing data, de novo assembly of Sanger and high-throughput sequencing data, SNP detection on whole genomes of any size, detection of structural variations on whole genomes of any size, ChIP-seq analysis, RNA-Seq analysis, small RNA analysis and BLAST. CLC bio also provides additional plugins that extend the platform for use in specific subject areas including genome finishing, microbial genomics, and structural biology. CLC bio's software allows the user to analyze, visualize, and compare genomic, transcriptomic, and epigenomic data from all major high-throughput sequencing platforms such as Illumina, Life Technologies, Roche 454, Pacific Biosciences, Oxford Nanopore, and Complete Genomics. CLC bio's software is platform independent and can be used for Mac OS X, Windows, and Linux. The platform includes both a desktop graphical user interface, command-line tools, a SOAP and REST API, and the ability to run containerized tools. CLC bio's analysis platform has been installed at several of the world's research institutions and at more than 2000 different organizations around the globe, including the top 10 pharmaceutical companies in the world.
Cloud Computing
In 2017, CLC bio launched their CLC Genomics Cloud Engine as a command-line driven platform for cloud-based bioinformatics workflow execution on Amazon Web Services. In 2019, this platform was adapted for and approved for use in AWS GovCloud. In 2020, CLC bio released a free plug-in that enables workflow execution on AWS directly from the CLC Genomics Workbench desktop software.
CLC bio started commercial activities on January 1, 2005 headquartered in Denmark. It is a profitable, privately owned company with 100 employees and has been acquired by Qiagen in late 2013. 30% of the employees have a PhD and another 50% have a MSc. CLC bio maintains a scientific focus by initializing and participating in various research projects around the world, including multiple projects funded by grants.
